Department of Immunology, Frimley Park Hospital NHS Foundation Trust, Portsmouth Road, Frimley, Camberley, Surrey, UK.
Clin Exp Immunol. 2011 Jan;163(1):96-103. doi: 10.1111/j.1365-2249.2010.04280.x. Epub 2010 Nov 9.
The considerable clinical heterogeneity of patients with common variable immunodeficiency disorders (CVID) shares some similarity with bone-marrow failure disorders such as Diamond-Blackfan anaemia (DBA) and Shwachman-Diamond syndrome (SDS), now recognized as defects in ribosome biogenesis or ribosomopathies. The recognition of a patient with DBA who subsequently developed CVID lends support to our previous finding of a heterozygous mutation in the SBDS gene of SBDS in another CVID patient, suggesting that ribosome biogenesis defects are responsible for a subset of CVID. Genetic defects in the ribosomal translational machinery responsible for various bone marrow failure syndromes are recognized readily when they manifest in children, but diagnosing these in adults presenting with complex phenotypes and hypogammaglobulinaemia can be a challenge. In this perspective paper, we discuss our clinical experience in CVID patients with ribosomopathies, and review the immunological abnormalities in other conditions associated with ribosomal dysfunction. With genetic testing available for various bone marrow failure syndromes, our hypothesis that ribosomal abnormalities may be present in patients with CVID could be proved in future studies by testing for mutations in specific ribosomal genes. New knowledge might then be translated into novel therapeutic strategies for patients in this group of immunodeficiency disorders.
普通变异性免疫缺陷病(CVID)患者的临床异质性相当大,与骨髓衰竭疾病如 Diamond-Blackfan 贫血(DBA)和 Shwachman-Diamond 综合征(SDS)有一些相似之处,现在被认为是核糖体生物发生缺陷或核糖体病。我们之前在另一名 CVID 患者中发现 SBDS 基因存在杂合突变,随后发现一名 DBA 患者也患有 CVID,这为我们的发现提供了支持,表明核糖体生物发生缺陷是 CVID 的一个亚组的原因。当核糖体翻译机制的遗传缺陷在儿童中表现出来时,很容易识别导致各种骨髓衰竭综合征的基因,但诊断在表现出复杂表型和低丙种球蛋白血症的成年人中存在这些缺陷可能具有挑战性。在本文中,我们讨论了我们在患有核糖体病的 CVID 患者中的临床经验,并回顾了与核糖体功能障碍相关的其他疾病中的免疫异常。随着各种骨髓衰竭综合征的基因检测可用,我们的假设,即核糖体异常可能存在于 CVID 患者中,未来的研究可以通过检测特定核糖体基因的突变来证明。新知识随后可能会转化为该组免疫缺陷疾病患者的新治疗策略。